Q) Not true about use of Bevacizumab (Free Ans)(Onco AIIMS)
a) It is a humanized monoclonal antibody against VEGF A
b) Bevacizumab is a first-line treatment in metastatic nonsquamous non-small cell lung cancer.
c) Bevacizumab is a first-line or second-line therapy for metastatic colorectal cancer
d) Its major advantage is that it has replaced combination chemotherapy
Ans d) It is used in combination with other drugs
d) Its major advantage is that it has replaced combination chemotherapy
a) True – Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis.
b) True – Bevacizumab is used as first-line treatment in combination with chemotherapy for metastatic nonsquamous non-small cell lung cancer (NSCLC).
c) True – Bevacizumab is used as first-line and second-line therapy in combination with chemotherapy for metastatic colorectal cancer.
d) Not true – Bevacizumab is not a replacement for combination chemotherapy. Instead, it is used in combination with standard chemotherapy regimens to improve efficacy. It is not used as a monotherapy in most settings.
